Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Rowers to cross Pacific Ocean to raise $28M for Parkinson’s research

Four endurance athletes, one of whom has Parkinson’s disease, have embarked on a 2,800-mile rowing journey across the Pacific Ocean this summer. The team’s goal is to raise $28 million for Parkinson’s research through The Michael J. Fox Foundation for Parkinson’s Research(MJFF). The “Team Human Powered Potential” aims…

AB-1005 gene therapy placed on fast track by regulators in US, UK

AskBio’s investigational gene therapy AB-1005 has been granted fast-track designation for Parkinson’s disease by the U.S. Food and Drug Administration (FDA), and innovation passport designation by the regulatory agency in the U.K. These designations are meant to accelerate the development and review process of therapy candidates designed to…

Anew Medical to advance development of Klotho gene therapy

Anew Medical said it will advance clinical development of its Klotho gene therapy program to prevent or stop the progression of neurodegenerative diseases, including Parkinson’s disease. Initial data suggest that maintaining high levels of the Klotho protein in the body may help people live longer and healthier…

MJFF $1.49M grant to advance preclinical research into KLS-13019

Kannalife Sciences has been awarded a $1.49 million grant from The Michael J. Fox Foundation (MJFF) to support the development of KLS-13019, the company’s novel cannabidiol- or CBD-derived therapy targeting neuroinflammation and mitochondrial dysfunction in Parkinson’s disease. KLS-13019 has shown promising results in preclinical models of…

Platform launched for sharing brain samples in Parkinson’s research

The Aligning Science Across Parkinson’s (ASAP) initiative has launched a data-sharing platform that will make data on human brain samples available to researchers around the world, furthering research into Parkinson’s disease. The ASAP CRN Cloud includes several brain sequencing collections obtained from samples from four ASAP Collaborative…

FDA OKs Parkinson’s clinical trial to test NouvNeu001 cell therapy

The U.S. Food and Drug Administration (FDA) has given Iregene Therapeutics the green light to launch a clinical trial testing its cell therapy NouvNeu001, being developed for moderate to advanced Parkinson’s disease. According to the company, this marks a significant milestone, with NouvNeu001 becoming the world’s first…

OneRF ablation system gets ICD-10-PCS CMS procedure code

NeuroOne Medical Technologies said the Centers for Medicare and Medicaid Services (CMS) granted a new ICD-10-PCS code to its OneRF Ablation procedure, a development the company said will lead to greater use of the technology. Effective Oct. 1, hospitals will be allowed to report inpatient procedures performed with…

Dopamine signaling linked to emotion recognition, study finds

Researchers at the University of Birmingham have shown that reducing dopamine signaling in the brain can impair people’s ability to recognize emotions or understand others’ mental states (mentalizing), symptoms that may be experienced by those with Parkinson’s disease. The study, “Disruption of dopamine D2/D3 system function impairs the…